Results 161 to 170 of about 89,305 (304)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. [PDF]

Theranostics
Kim RK, Heo CK, Choi MJ, Kahm YJ, Kim MK, Lee M, Lee JY, Park H, Jung U, Shin BC, Kim BJ, Kim SC, Cho EW, Ryu CJ, Kim IG.   +14 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

The SIRP family: from structural diversity and signaling mechanisms to implications in immune-related disease targeted therapeutics. [PDF]

Front Immunol
Jin Y, Huang Q, Song J, Abideen ZU, Tan R, Xu S, Chen M.   +6 more
europepmc   +1 more source

Case Report: A case of severe hypotension induced by nimotuzumab in a nasopharyngeal carcinoma patient. [PDF]

Front Immunol
Liu W, Qin P, Xiao F, Sun B.
europepmc   +1 more source

Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. [PDF]

Int J Mol Sci
Deb Nath T, Mukherjee A, Chauhan SC, Bandyopadhyay D.   +3 more
europepmc   +1 more source

Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy

Clinical &Experimental Allergy, EarlyView.
Mapping IgG epitopes of the major birch allergen Bet v 1 identified patient‐derived, hypoallergenic peptides that did not trigger degranulation. These findings support a novel, safer approach for peptide‐based allergen immunotherapy that leverages naturally induced IgG specificities from allergic individuals. ABSTRACT Background Allergen immunotherapy (
Lara Šošić, Marta Paolucci, Alessandro Streuli, David A. Melillo, Tianchi Jiang, Raffaela Campana, Claudia C. V. Lang, Thomas M. Kündig, Christian Steuer, Klaus Eyer, Pål Johansen   +10 more
wiley   +1 more source

Clinical application and optimization strategies for antibody-drug conjugates in solid tumors. [PDF]

J Int Med Res
Qu J, Zhao X, Zhang L, Cai W, Shen M, Liu X, Wei X, Fei F.   +7 more
europepmc   +1 more source

Structural Determination of a Human IgE Epitope on Major Birch Allergen Bet v 1

Allergy, EarlyView.
Andrea O'Malley, Brooke T. Borders, Jeffrey M. Wilson, Scott A. Smith, Maksymilian Chruszcz   +4 more
wiley   +1 more source

Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell‐Derived NK Cell Therapies

Cell Proliferation, EarlyView.
Advancements in the generation of human pluripotent stem cell‐derived natural killer (PSC‐NK) cells have attracted considerable attention within the biomedical research community, offering a promising off‐the‐shelf technique for universal immune therapy.
Qianwen Chen, Jianwei Lv, Xinwei Xie, Hanlin Zhu, Zhenyu Xiao, Yaojin Peng   +5 more
wiley   +1 more source